The FUJIFILM SonoSite iViz Ultrasound System is a general purpose ultrasound system and non-continuous patient monitoring platform intended in clinical care by qualified physicians and healthcare professionals for evaluation by ultrasound imaging or fluid flow analysis of the human body. Specific clinical applications and exam types include:

Fetal - OB Abdominal Pediatric Cardiac Adult Cardiac Pediatric

Device Description

The SonoSite iViz Ultrasound System is a highly featured, general purpose, software controlled, diagnostic ultrasound system used to acquire and display high-resolution, real-time ultrasound data through multiple imaging modes. iViz is a custom fabricated digital electronic handheld tablet that is highly portable, battery-operated, and consists of an active transducer that connects to and is controlled by the tablet. iViz supports Bluetooth and wireless network connectivity for image transfer and over-the-air (OTA) software updates.

AI/ML Overview

This document is a 510(k) premarket notification for the FUJIFILM SonoSite iViz Ultrasound System, dated November 12, 2015. It focuses on demonstrating substantial equivalence to predicate devices rather than proving specific performance metrics against defined acceptance criteria. Therefore, most of the requested information regarding acceptance criteria, proven device performance through a study, expert involvement, and ground truth establishment is not present in this document.

Here's an analysis based on the provided text:

1. A table of acceptance criteria and the reported device performance:

The document does not provide a table of acceptance criteria for specific performance metrics (e.g., accuracy, sensitivity, specificity) or report quantitative device performance data. Instead, it relies on demonstrating substantial equivalence to predicate devices by comparing intended use, technological characteristics, and conformance to recognized safety standards.

The closest to "acceptance criteria" are the standards it aims to comply with, listed in the "Summary of Non-Clinical Tests" section:

Reference No.	Title
ISO 10993-1	AAMI / ANSI / ISO 10993-1:2009/(R)2013, Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process
IEC 60601-1	AAMI / ANSI ES60601-1:2005/(R)2012 and A1:2012, C1:2009/(R)2012 and A2:2010/(R)2012 (Consolidated Text) Medical electrical equipment - Part 1: General requirements for basic safety and essential performance (IEC 60601-1:2005, MOD)
IEC 60601-1-2	AAMI / ANSI / IEC 60601-1-2:2007(R)2012, Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral standard: Electromagnetic compatibility - Requirements and tests (Edition 3)
IEC 60601-1-6	IEC 60601-1-6 Edition 3.1 2013-10, Medical electrical equipment - Part 1-6: General requirements for basic safety and essential performance - Collateral standard: Usability
IEC 60601-2-37	IEC 60601-2-37:2007 Edition 2.0 2007-08, Medical electrical equipment - Part 2-37: Particular requirements for the basic safety and essential performance of ultrasonic medical diagnostic and monitoring equipment
IEC 62304	AAMI / ANSI / IEC 62304:2006, Medical device software - Software life cycle processes
IEC 62359	IEC 62359 Edition 2.0 2010-10-10, Ultrasonics – Field characterization – Test methods for the determination of thermal and mechanical indices related to medical diagnostic ultrasonic fields [Including: Technical corrigendum 1 (2011)]
ISO 14971	ISO 14971:2007, Medical devices - Application of risk management to medical devices
NEMA UD 2-2004	Acoustic Output Measurement Standard for Diagnostic Ultrasound Equipment

The "reported device performance" is implicitly stated as "the device has been found to conform to applicable mandatory medical device safety standards" and "Assurance of quality was established by employing the following elements of product development but were not limited to: Design Phase Reviews, Risk Assessment, Requirements Development, and Verification and Validation."

2. Sample size used for the test set and the data provenance:

The document explicitly states: "The iViz Ultrasound System and transducers, subject of this submission, did not require clinical studies to support the determination of substantial equivalence." This means there was no test set of patient data used for clinical performance evaluation. The evaluation was based on non-clinical tests (electrical, thermal, mechanical, EMC safety, cleaning/disinfection, biocompatibility, acoustic output) and comparison to predicate devices.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

Since no clinical study was conducted using a test set of patient data, there were no experts involved in establishing ground truth for a test set in this context.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set:

Not applicable, as no clinical test set was used.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

Not applicable. This device is an ultrasound system, not an AI-powered image analysis tool that would typically be evaluated with MRMC studies for human reader improvement. The submission is for the base ultrasound system.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

Not applicable. This device is a diagnostic ultrasound system intended for use by a "qualified physician and healthcare professionals," implying human operation and interpretation. It is not a standalone algorithm.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc):

Not applicable. No clinical ground truth was established from patient data. The "ground truth" for the non-clinical tests would be the specifications and requirements defined by the referenced standards.

8. The sample size for the training set:

Not applicable. This document describes a medical device clearance process based on substantial equivalence, not the training of an AI algorithm. There is no mention of a "training set" in the context of machine learning.

9. How the ground truth for the training set was established:
Not applicable, as no training set for an algorithm was mentioned or used for this submission.

In summary, the provided document is a 510(k) submission for an ultrasound system, demonstrating its safety and effectiveness through substantial equivalence to existing predicate devices and compliance with recognized industrial standards, rather than through clinical performance studies against specific acceptance criteria for diagnostic accuracy or through AI algorithm validation.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized symbol of three human profiles facing to the right, arranged in a stacked, overlapping manner.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

November 12, 2015

FUJIFILM Sonosite, Inc. % Mr. Mark Job Responsible Third Party Official Regulatory Technology Services LLC 1394 25th Street. NW BUFFALO MN 55313

Re: K152983

Trade/Device Name: FUJIFILM SonoSite iViz Ultrasound System Regulation Number: 21 CFR 892.1550 Regulation Name: Ultrasonic pulsed doppler imaging system Regulatory Class: II Product Code: IYN, IYO, ITX Dated: October 8, 2015 Received: October 13, 2015

Dear Mr. Job:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Robert Ocks

Robert Ochs. Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) BB K152983

Device Name FUJIFILM SonoSite iViz Ultrasound System

Indications for Use (Describe)

Fetal - OB Abdominal Pediatric Cardiac Adult Cardiac Pediatric

Type of Use (Select one or both, as applicable)

Registration Use (Part 21 CFR 601 Subpart D)
Over-The-Counter Use (21 CFR 601 Subpart C)

Prescription Use (Part 21 CFR 801 Subpart D)

| | Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Table 1.3-1: Diagnostic Ultrasound Indications for Use Form – FUJIFILM SonoSite iViz Ultrasound System

System:	FUJIFILM SonoSite iViz Ultrasound System
Transducer:	N/A
Intended Use:	Diagnostic ultrasound imaging or fluid flow analysis of the humanbody as follows:
Clinical Application	B	M	PWD	CWD	ColorDoppler	Combined(Spec.)	Other(Spec.)
Ophthalmic
Fetal	N	N			N	B+M; B+CD	1-3
Abdominal	N	N			N	B+M; B+CD	1-3
Intra-operative (Abdominalorgans and vascular)
Intra-operative (Neuro.)
Laparoscopic
Pediatric	N	N			N	B+M; B+CD	1-3
Small Organ (breast, thyroid,testicles, prostate)
Neonatal Cephalic
Adult Cephalic
Trans-rectal
Trans-vaginal
Trans-urethral
Trans-esoph. (non-Card.)
Musculo-skel. (Convent.)
Musculo-skel. (Superfic.)
Intra-luminal
Other (spec.)
Cardiac Adult	N	N			N	B+M; B+CD	1-3
Cardiac Pediatric	N	N			N	B+M; B+CD	1-3
Trans-esophageal (card.)
Other (spec.)
Peripheral vessel
Other (spec.)

N= new indication; P= previously cleared by FDA; E= added under this appendix

Additional Comments:

1: Color Doppler includes Power/Velocity/Variance

2: Tissue Harmonic Imaging (THI)

3: SonoHD3 Imaging (Speckle Reduction)

Prescription Use (Per 21 CFR 801.109)

{4}------------------------------------------------

System:	FUJIFILM SonoSite iViz Ultrasound System
Transducer:	P21v/5-1 MHz Transducer
Intended Use:	Diagnostic ultrasound imaging or fluid flow analysis of the human
	body as follows:
Clinical Application	Mode of Operation
	B	M	PWD	CWD	ColorDoppler	Combined(Spec.)	Other(Spec.)
Ophthalmic
Fetal	N	N			N	B+M; B+CD	1-3
Abdominal	N	N			N	B+M; B+CD	1-3
Intra-operative (Abdominalorgans and vascular)
Intra-operative (Neuro.)
Laparoscopic
Pediatric	N	N			N	B+M; B+CD	1-3
Small Organ (breast, thyroid,testicles, prostate)
Neonatal Cephalic
Adult Cephalic
Trans-rectal
Trans-vaginal
Trans-urethral
Trans-esoph. (non-Card.)
Musculo-skel. (Convent.)
Musculo-skel. (Superfic.)
Intra-luminal
Other (spec.)
Cardiac Adult	N	N			N	B+M; B+CD	1-3
Cardiac Pediatric	N	N			N	B+M; B+CD	1-3
Trans-esophageal (card.)
Other (spec.)
Peripheral vessel
Other (spec.)

Table 1.3-2: Diagnostic Ultrasound Indications for Use Form – P21v/5-1 Transducer

N= new indication; P= previously cleared by FDA; E= added under this appendix

Additional Comments:

1: Color Doppler includes Power/Velocity/Variance
2: Tissue Harmonic Imaging (THI)

3: SonoHD3 Imaging (Speckle Reduction)

Prescription Use (Per 21 CFR 801.109)

{5}------------------------------------------------

510(K) Summary

This summary of safety and effectiveness is provided as part of this Premarket Notification in compliance with 21 CFR, Part 807, Subpart E, Section 807.92.

1) Submitter's name, address, telephone number, contact person:

FUJIFILM SonoSite, Inc. 21919 30th Drive SE Bothell, WA 98021-3904

Corresponding Official:	Patricia LiauManager, Regulatory Affairs
E-mail:	Patricia.Liau@sonosite.com
Telephone:	(425) 951-6870
Facsimile:	(425) 951-1201
Date prepared:	September 28, 2015

2) Name of the device, including the trade or proprietary name if applicable, the common or usual name, and the classification name, if known:

Common/ Usual Name

Diagnostic Ultrasound System with Accessories

Proprietary Name

SonoSite iViz Ultrasound System (subject to change)

Classification Names

Name	FR Number	Product Code
Ultrasonic Pulsed Doppler Imaging System	892.1550	90-IYN
Ultrasonic Pulsed Echo Imaging System	892.1560	90-IYO
Diagnostic Ultrasound Transducer	892.1570	90-ITX

3) Identification of the predicate or legally marketed device:

SonoSite Edge Ultrasound System	K133454
Philips Nuvis Ultrasound System	K133833

4) Device Description:

5) Intended Use:

The FUJIFILM SonoSite iViz Ultrasound System is a general purpose ultrasound system and non-

{6}------------------------------------------------

continuous patient monitoring platform intended in clinical care by qualified physicians and healthcare professionals for evaluation by ultrasound imaging or fluid flow analysis of the human body. Specific clinical applications and exam types include:

Fetal - OB Abdominal Pediatric Cardiac Adult Cardiac Pediatric

6) Technological Characteristics:

SonoSite iViz and Edge, and Philips Nuvis Ultrasound Systems are Track 3 devices that employ the same fundamental scientific technology. A comparison table is provided below.

Feature	SonoSite iViz UltrasoundSystem(This submission)	SonoSite EdgeUltrasound System(K133454)	Philips Nuvis UltrasoundSystem(K133833)
Intended Use	Diagnostic ultrasound imaging orfluid flow analysis of the humanbody	Diagnostic ultrasound imaging orfluid flow analysis of the humanbody	Diagnostic ultrasound imaging orfluid flow analysis of the humanbody
Indications forUse	Fetal - OBAbdominalPediatricCardiac AdultCardiac Pediatric	OphthalmicFetal - OB/GYNAbdominalIntraoperative (abdominal organsand vascular)Intra-operative (Neuro.)PediatricSmall Organ (breast, thyroid,testicle, prostate)Neonatal CephalicAdult CephalicTrans-RectalTrans-VaginalMusculo-skeletal (Conventional)Musculo-skeletal (Superficial)Cardiac AdultCardiac PediatricTrans-esophageal (cardiac)Peripheral VesselNeedle guidance	Fetal - OBAbdominalOther (Urology)Other (Gynecology)Other (Fetal Echo)
TransducerTypes	Phased Array	Linear ArrayCurved Linear ArrayIntracavitaryPhased ArrayStatic ProbesTrans-esophageal	Curved Linear Array
TransducerFrequency	1.0 – 5.0 MHz	1.0 - 15.0 MHz	2.0 – 5.0 MHz
Modes ofOperation	B-mode Grayscale ImagingTissue Harmonic ImagingM-modeColor M-ModeColor Power DopplerZoomCombination ModesSonoHD3 Noise ReductionVelocity Color Doppler	B-mode Grayscale ImagingTissue Harmonic ImagingM-modeColor M-ModeColor Power DopplerZoomCombination ModesPulsed Wave (PW) DopplerContinuous Wave (CW) DopplerSonoHD2 Noise ReductionSonoMB/MBe ImageCompoundingSteered CW DopplerVelocity Color DopplerTissue Doppler Imaging (TDI)	B-mode Grayscale ImagingColor Power DopplerCombination ModesVelocity Color Doppler

{7}------------------------------------------------

Feature	SonoSite iViz UltrasoundSystem(This submission)	SonoSite EdgeUltrasound System(K133454)	Philips Nuvis UltrasoundSystem(K133833)
PW Doppler	Not available	Available	Not available
CW Doppler	Not available	Available	Not available
PatientContactMaterials	Transducers:Polysulfone UDEL P1700Poly-Vinyl-Chloride (PVC)Silicone Rubber	Transducers:Acrylonitrile-butadien-styrene(ABS)CycoloyDow Medical Adhesive, Type AEpoxy paste adhesivePolyethylene (PE) IonomerPolyetheretherketone (PEEK)Polysulfone UDEL P1700PolyurethanePoly-Vinyl-Chloride (PVC)Silicone RTV AdhesiveSilicone RubberUrethaneNeedle Guides:Acetal copolymerAcrylonitrile-butadien-styrene(ABS)	Information not publicly available
System	iViz:	Edge:	Nuvis:
Characteristics	Handheld tablet7", 1920 x 1200 pixels LCDOperating system: AndroidiViz ultrasound software runningas an "app" on tabletSystem operates via batteryWireless 802.11 support for imagetransfer and over-the-air (OTA)software updates	Handheld display and control12.1", 800 x 600 pixels, LCDOperating system: Windows CESystem operates via battery or ACpowerWireless 802.11 support for imagetransfer	Handheld tablet (COTS Nexus 7)7", 1280 x 800 pixels LCDOperating system: AndroidNuvis ultrasound software runningas an "app" on COTS tabletSystem operates via batteryWireless 802.11 support for imagetransfer (non-DICOM)
510(k) Track	Track 3	Track 3	Track 3

7) Determination of Substantial Equivalence:

Summary of Non-Clinical Tests:

The iViz Ultrasound System has been evaluated for electrical, thermal, mechanical, and EMC safety. Additionally, cleaning/disinfection, biocompatibility, and acoustic output have been evaluated, and the device has been found to conform to applicable mandatory medical device safety standards. Assurance of quality was established by employing the following elements of product development but were not limited to: Design Phase Reviews, Risk Assessment, Requirements Development, and Verification and Validation.

The iViz Ultrasound System is designed to comply with the following FDA recognized standards.

Reference No.	Title
ISO 10993-1	AAMI / ANSI / ISO 10993-1:2009/(R)2013, Biological evaluation of medical devices -Part 1: Evaluation and testing within a risk management process
IEC 60601-1	AAMI / ANSI ES60601-1:2005/(R)2012 and A1:2012, C1:2009/(R)2012 andA2:2010/(R)2012 (Consolidated Text) Medical electrical equipment - Part 1: Generalrequirements for basic safety and essential performance (IEC 60601-1:2005, MOD)
IEC 60601-1-2	AAMI / ANSI / IEC 60601-1-2:2007(R)2012, Medical electrical equipment - Part 1-2:General requirements for basic safety and essential performance - Collateralstandard: Electromagnetic compatibility - Requirements and tests (Edition 3)
IEC 60601-1-6	IEC 60601-1-6 Edition 3.1 2013-10, Medical electrical equipment - Part 1-6: Generalrequirements for basic safety and essential performance - Collateral standard:Usability
IEC 60601-2-37	IEC 60601-2-37:2007 Edition 2.0 2007-08, Medical electrical equipment - Part 2-37:Particular requirements for the basic safety and essential performance of ultrasonic

{8}------------------------------------------------

Reference No.	Title
	medical diagnostic and monitoring equipment
IEC 62304	AAMI / ANSI / IEC 62304:2006, Medical device software - Software life cycleprocesses
IEC 62359	IEC 62359 Edition 2.0 2010-10-10, Ultrasonics – Field characterization – Testmethods for the determination of thermal and mechanical indices related to medicaldiagnostic ultrasonic fields [Including: Technical corrigendum 1 (2011)]
ISO 14971	ISO 14971:2007, Medical devices - Application of risk management to medicaldevices
NEMA UD 2-2004	Acoustic Output Measurement Standard for Diagnostic Ultrasound Equipment

Summary of Clinical Tests:

The iViz Ultrasound System and transducers, subject of this submission, did not require clinical studies to support the determination of substantial equivalence.

8) Conclusion:

Intended uses and other key features are consistent with traditional clinical practice and FDA guidance. The iViz system and predicates meet FDA requirements for Track 3 devices, share indications for use, have biosafety equivalence, and conform to applicable electromedical device safety standards. FUJIFILM SonoSite, Inc. believes that the iViz Ultrasound System is substantially equivalent with regard to safety and effectiveness to the predicate devices.

Regulation Number and Section

§ 892.1550 Ultrasonic pulsed doppler imaging system.

(a)
Identification. An ultrasonic pulsed doppler imaging system is a device that combines the features of continuous wave doppler-effect technology with pulsed-echo effect technology and is intended to determine stationary body tissue characteristics, such as depth or location of tissue interfaces or dynamic tissue characteristics such as velocity of blood or tissue motion. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.